According to the results, CC, KIRC, LIHC, PAAD, LUAD, and UCEC patients with the C2 and C3 subtypes—that is, a hotter tumor immune microenvironment and a better response to immunotherapy—had the highest levels of RIPOR2 expression (Figure 7G). The gene discussed is RIPOR2; the disease is neoplasm.